In summary, our data show that HMGB1 deficiency and reduced HMGB1 expression occur in a broad range of different tumor entities and that low rather than high HMGB1 expression is often linked to an aggressive tumor phenotype, thereby bridging the gap between basic molecular insights and clinical applications in cancer. This evidence concerns the gene HMGB1 and neoplasm.